What are the side effects of Linvoseltamab?

Linvoseltamab (rivosetantumab) is a new bispecific antibody for relapsed or refractory multiple myeloma (R/RMM). It mainly induces T cell immune responses by targeting B cell maturation antigen (BCMA). Although its clinical application has brought new hope, it is also inevitably accompanied by some side effects and adverse reactions.

In the clinical study of Linvoseltamab, researchers observed some common adverse reactions. These side effects mainly include musculoskeletal pain, cytokine release syndrome, cough, upper respiratory tract infection, diarrhea, fatigue, pneumonia, nausea, headache and dyspnea. Among them, cytokine release syndrome (CRS) is a more serious side effect, which usually occurs within a few days after taking the drug and manifests as fever, fatigue, muscle and joint pain and other symptoms. Some patients may develop more serious complications, which require timely management and treatment.

In addition,Linvoseltamab may cause some laboratory abnormalities. According to clinical studies, common grade 3 or 4 laboratory abnormalities include decreased lymphocyte count, decreased neutrophil count, decreased hemoglobin, and decreased white blood cell count. These conditions may affect the patient's immune function and overall health status. During the monitoring process, doctors need to regularly check the patient's blood indicators in order to detect and deal with these adverse reactions in a timely manner.

In addition,The use of Linvoseltamab also has potential effects on the nervous system, including immune effector cell-associated neurotoxic syndrome (ICANS). Such neurotoxic symptoms may manifest as confusion, speech impairment, motor coordination problems, etc., and in severe cases may even lead to a decrease in the patient's quality of life. Therefore, during medication, doctors need to closely observe the patient's neurological status and conduct appropriate assessment and intervention for any abnormal manifestations.

Reference materials:https://en.wikipedia.org/wiki/Linvoseltamab